Navigation Links
Glycosan BioSystems Seeks CE Mark in the European Union for HyStem-Rx, a Unique, Implantable Scaffold for Tissue Engineering

SALT LAKE CITY, June 1 /PRNewswire/ -- Glycosan BioSystems announced today that the Company has begun the process for gaining regulatory approval within the European Union for the use of HyStem-Rx as a resorbable scaffold for implanting autologous adipose derived cells in reconstruction and aesthetic plastic surgery procedures.  Upon approval, HyStem-Rx will receive a CE Mark as an implantable medical device.  HyStem-Rx will be indicated for use to correct subcutaneous contour defects arising from traumatic injury, oncologic resections, and other conditions that result in the loss of adipose tissue.

Spokesman for the Company said, "There is increasing recognition that development of successful cell-based therapies will require implanting cells within a matrix to protect them from natural inflammatory processes and to provide a three dimensional scaffold on which cells can attach and proliferate.  HyStem-Rx is a unique biomaterial that was designed as a biocompatible, resorbable mimic of the extra-cellular matrix to be used as a delivery matrix in cell-based therapies.   Pre-clinical studies have shown HyStem-Rx to support the growth of a wide variety of cell types and the proliferation and differentiation of embryonic stem cells as well as neural, hepatic, and adipose derived progenitor cells."

Glycosan BioSystems, Inc. is a privately held Salt Lake City biotechnology company that develops, manufactures, and sells unique biocompatible hydrogels that mimic the extracellular matrix, the complex mixture of macromolecules that holds cells together in tissues and organs.  The Company's products are used in cell culture and stem cell research and have applications as implantable, resorbable scaffolds for tissue engineering, regenerative medicine, and cell-based therapies.  Glycosan is the licensee of the University of Utah Research Foundation for certain intellectual property based on unique chemical cross-linking strategy to prepare hyaluronan based hydrogels from chemically modified hyaluronan and other extracellular matrix constituents.  More information on the Company and its products can be found at

SOURCE Glycosan BioSystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Online Tutorials for NCBI resources BioSystems and DCODE
2. Microbix Biosystems Re-files Annual Results With OSC
3. Microbix Biosystems Provides a Corporate Update
4. Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited
5. Penguin Computing Forms OEM Agreement with Applied Biosystems for Scyld ClusterWare
6. WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research
7. Prosolia and Indigo BioSystems Come Together to Create FireFly(TM) Data Conversion Software for Mass Spectrometers
8. Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research
9. Cyprotex Purchases Applied Biosystems Sciex QTRAP(R) 5500 LC-MS/MS
10. Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfection Reagent
11. Enigma Diagnostics Announces Patent Licence With Applied Biosystems
Post Your Comments:
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") ( ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):